 | |
| Clinical data | |
|---|---|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.011.169 |
| Chemical and physical data | |
| Formula | C9H4Cl3IO |
| Molar mass | 361.38 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 113.5 °C (236.3 °F) |
| Solubility in water | Insoluble mg/mL (20 °C) |
| |
| |
| (verify) | |
Haloprogin is an antifungal drug used to treat athlete's foot and other fungal infections.[1] It is marketed in creams under the trade names Halotex, Mycanden, Mycilan, and Polik.
Action
Haloprogin was previously used in 1% topical creams as an antifungal agent. It was marketed over-the-counter primarily to treat tinea infections of the skin. The mechanism of action is unknown.[2]
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.[3]
References
- ^ Rudolph RI (December 1979). "Haloprogin as treatment for fungal infections". Clinical and Experimental Dermatology. 4 (4): 548. doi:10.1111/j.1365-2230.1979.tb01656.x. PMID 161212. S2CID 71471801.
- ^ "Haloprogin". Drugs@FDA. Food and Drug Administration. Retrieved 2007-02-17.
- ^ "Haloprogin". DrugBank. University of Alberta. Nov 6, 2006. Retrieved 2007-02-17.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 30 January 2023, at 13:45